Kirkland Advises Catalyst Pharmaceuticals on $4.1 Billion Sale to Angelini

Kirkland & Ellis advised Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, on a definitive agreement to be acquired by Angelini Pharma S.p.A., an international pharmaceutical company and part of the Angelini Industries Group. Angelini Pharma has agreed to acquire all outstanding shares of Catalyst for $31.50 per share in cash, for a total equity value of approximately $4.1 billion (equivalent to 3.5 billion euros.) The transaction has been unanimously approved by the boards of directors of both companies and is expected to close in the third quarter of 2026.

Read the transaction press release

The Kirkland team included corporate lawyers Graham Robinson, Chadé Severin, Merric Kaufman, Zohra Yaqhubi, Eric Solomine, Amy Tong, Julianne Turner and Mark Sibold; executive compensation lawyers Timothy F. Nelson and Andrea Rosato; employee benefits lawyers Justin Coddington, Caitlin Bradford and Carly Krause; employment & labor lawyers Risa Salins, Jon Link and Kayla Garcia; healthcare transactions lawyers Dennis Williams, Lindsay Borgeson, Cooper Barghols and Isabelle Breier; technology & IP transactions lawyers Shellie Freedman, Rami Sherman and Yeram Choi; antitrust & competition lawyers Liz Kraus, Maria Raptis and Alyssa Hartley; international trade & national security lawyer John Kabealo; litigation lawyers Stefan Atkinson and Alyssa Scruggs; tax lawyers Liam Murphy and Tex Adkins; and debt finance lawyer Andy Veit.